Delivra publishes positive results utilizing its novel platform technology for Varicose Veins
TORONTO: Delivra Corp. (TSXV: DVA - Delivra or the Company) today announced the publication of positive data from a clinical study demonstrating the safety and efficacy to treat chronic venous insufficiency of lower limbs, using the LivReliefTM Varicose Vein Cream over-the-counter product. These results were published in the respected peer-reviewed scientific journal, PLOS ONE.
This impressive data further validates Delivra's platform technology, offering patients an effective, safe and convenient over-the-counter cream for varicose vein treatment. Our robust over-the-counter product development and pharmaceutical pipeline of high-value innovative products provide an array of unique commercialization opportunities. LivReliefTM Varicose Vein Cream, along with LivReliefTM Pain Relief Cream, LivReliefTM Extra Strength Chronic Angry Pain Relief Cream and LivReliefTM Sports & Active Pain Relief Cream can be found in over 6,000 retail outlets across Canada, said Dr. Joseph Gabriele, CEO of Delivra.